MDP.V - Medexus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
4.4000
0.0000 (0.00%)
As of 3:58PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.4000
Open4.2500
Bid4.3000 x 0
Ask4.4800 x 0
Day's Range4.2500 - 4.4000
52 Week Range3.8000 - 7.3500
Volume7,243
Avg. Volume6,518
Market Cap73.45M
Beta (3Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)-0.8650
Earnings DateJun 27, 2019 - Jul 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.75
  • GlobeNewswire9 days ago

    Medexus Pharmaceuticals Announces Normal Course Issuer Bid

    MONTREAL, Quebec, May 14, 2019 -- Medexus Pharmaceuticals Inc.  (the “Company”) (TSXV: MDP, OTCQB: PDDPF) announced today it has submitted to the TSX Venture Exchange (the.

  • GlobeNewswire16 days ago

    Medexus Pharmaceuticals Launches New Metoject® Subcutaneous 15mg Dosage for the Treatment of Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis in Canada

    Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose in Canada. Metoject Subcutaneous is a pre-filled syringe of methotrexate with a pre-attached subcutaneous needle that is approved in Canada for the treatment of rheumatoid arthritis, psoriasis and psoriatic arthritis.

  • GlobeNewswirelast month

    Medexus CEO to Present at Two Upcoming Investor Conferences

    Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) announces that Ken d’Entremont, Chief Executive Officer, has been invited to present and meet with investors at two upcoming investor conferences. Medexus is scheduled to present at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30, 2019 at 11:00 a.m., Eastern Time, with several one-on-one meetings to be held throughout the two days. Additionally, the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 4:30 p.m., Eastern Time, which is being held at The Mandarin Oriental Hotel in New York City.

  • Can You Imagine How Medexus Pharmaceuticals's (CVE:MDP) Shareholders Feel About The 73% Share Price Increase?
    Simply Wall St.2 months ago

    Can You Imagine How Medexus Pharmaceuticals's (CVE:MDP) Shareholders Feel About The 73% Share Price Increase?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...

  • ACCESSWIRE2 months ago

    LD Micro Virtual Conference Is Live, March 12th and 13th

    LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...

  • ACCESSWIRE2 months ago

    Medexus to Present at the 2019 LD Micro Virtual Conference

    MONTREAL, CA / ACCESSWIRE / March 8, 2019 / Medexus Pharmaceuticals Inc. (the "Company" or "Medexus") (TSXV: MDP, OTCQB: PDDPF) today announced that it will be presenting at the second annual LD Micro Virtual Conference on Tuesday, March 12th at 10:20 AM EST / 7:20 AM PST. Ken d'Entremont, Chief Executive Officer and Roland Boivin, Chief Financial Officer, of Medexus, will be giving the presentation and answering questions from investors. "We are delighted to be hosting our second virtual event in order to showcase some of the truly unique names in micro-cap," stated Chris Lahiji, President of LD Micro.

  • GlobeNewswire3 months ago

    Medexus Granted Authorization by Health Canada to Distribute Treosulfan in Canada

    Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that Health Canada has authorized the Company to distribute Treosulfan, a conditioning agent used prior to stem cell transplantation.  Authorization was granted via the Special Access Program which allows healthcare practitioners to access non-marketed drugs to treat patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. Medexus plans to file for registration of Treosulfan with Health Canada in 2019 and expects to receive full registration within 12 to 18 months following the application. Medexus acquired the rights to Treosulfan through the acquisition of Medac Pharma, Inc., in the fall of 2018.

  • GlobeNewswire3 months ago

    Medexus Enters into Expanded Licensing Agreement for Gliolan® in Canada

    Medexus Pharmaceuticals Inc.  (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it has entered into a licensing agreement with photonamic GmbH & Co. KG (“photonamic”) for the exclusive rights to market and distribute Gliolan® in Canada, which assists neurosurgeons to better visualize and more completely remove malignant brain tumors (gliomas) by causing them to become fluorescent and glow during surgery. Health Canada previously granted Medexus authorization to distribute Gliolan in Canada via the Special Access Program (“SAP”), which provides healthcare practitioners with access to non-marketed drugs to treat patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable.

  • GlobeNewswire3 months ago

    Medexus Pharmaceuticals Announces 512% Increase in Revenue to $14.4 Million for the Third Quarter of Fiscal 2019

    Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its operating and financial results for the fiscal third quarter ended December 31, 2018. The integration is progressing as planned, and we are just now beginning to see the synergies of the combination, which should contribute to improved profitability going forward.

  • When Will Medexus Pharmaceuticals Inc. (CVE:MDP) Breakeven?
    Simply Wall St.3 months ago

    When Will Medexus Pharmaceuticals Inc. (CVE:MDP) Breakeven?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Medexus Pharmaceuticals Inc.'s (CVE:MDP): Medexus Pharmaceuticals Inc.Read More...

  • GlobeNewswire3 months ago

    Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2019 Conference Call

    MONTREAL, Feb. 13, 2019 (GLOBE NEWSWIRE) --  Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 4:30 PM Eastern Time on Monday, February 25, 2019 to discuss the Company’s financial results for the fiscal third quarter ended December 31, 2018, as well as the Company’s corporate progress and other developments. The Company also announced it has retained Crescendo Communications, LLC ("Crescendo”) to provide investor relations services for the Company.

  • GlobeNewswire3 months ago

    Medexus Lists October 2018 Unsecured Convertible Debentures on the TSX Venture Exchange

    MONTREAL, Feb. 12, 2019 -- Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced that the 6.0% unsecured convertible.

  • GlobeNewswire4 months ago

    Medexus Files Business Acquisition Report

    Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the “Company”) (TSXV: MDP, OTCQB: PDDPF) today announced the filing of the Business Acquisition Report (“BAR”) on SEDAR (www.sedar.com) in relation to the previously announced transaction that occurred on October 16, 2018. “As can be seen in the unaudited interim financial statements (non-IFRS compliant) for the period ended Sept 30, 2018 included in the BAR, both Medexus Inc. and medac Pharma, Inc. have strong revenue growth resulting in significant positive Net Income” stated Ken d’Entremont, Chief Executive Officer of the Company. Medexus Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong North American commercial platform.